Viemed Healthcare, Inc.

Health Care
Misc Health and Biotechnology Services
www.viemed.com

Earnings Score
Moat Score
Safety Score

Market Cap $260.22M
PE 21
Debt $3.92M
Cash $10.16M
EV $253.98M
FCF -$6.48M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	$12.29M
EBIT	$19.54M
ROE	9%
ROA	11%
FCF	-$6.48M
Equity	$136.75M
Growth Stability	38%
PE	21.18
PEG	-1.18
PB	1.9
P/FCF	-40.16
P/S	1.12
Price/Cash	0.04
Debt/Equity	0.03
Debt/FCF	-0.6
Net Margins	4%
Gross Margins	59%
Op. Margins	8%
Earnings CAGR	-6%
Sales Growth YoY	17%
Sales Growth QoQ	-3%
Sales CAGR	20%
FCF CAGR	-9%
Equity CAGR	25%
Earnings Stability	-0.29
Earnings Growth YoY	64%
Earnings Growth QoQ	-39%

Earnings CAGR 5Y	-18%
Sales CAGR 5Y	17%
FCF CAGR 5Y	-21%
Equity CAGR 5Y	13%
Earnings CAGR 3Y	27%
Sales CAGR 3Y	27%
FCF CAGR 3Y	70%
Equity CAGR 3Y	16%
Market Cap	$260.22M
Revenue	$232.79M
Assets	$178.08M
Total Debt	$3.92M
Cash	$10.16M
Shares Outstanding	39.43M
EV	253.98M
Earnings Score	6%
Moat Score	86%
Safety Score	38%
Final Score	43%
Working Capital	13.63M
Current Ratio	1.38
Gross Profit	$136.68M
Shares Growth 3y	1%
Equity Growth QoQ	3%
Equity Growth YoY	18%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Viemed Healthcare Inc is a provider of equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services to neuromuscular patients.

SEC Filings

Direct access to Viemed Healthcare, Inc. (VMD) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2025
- 10-Q Mar 31
2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Viemed Healthcare, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Viemed Healthcare, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -6%

Stability -29%

loading chart...

Viemed Healthcare, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Viemed Healthcare, Inc..

Years

Calculation mode

= -$35M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$6.5M	-$5.9M	-$5.3M	-$4.8M	-$4.4M	-$4M	-$3.6M	-$3.3M	-$3M	-$2.7M	-$2.4M	-$24M
DCF		-$5.3M	-$4.4M	-$3.6M	-$3M	-$2.5M	-$2M	-$1.7M	-$1.4M	-$1.1M	-$935K	-$9.4M
Value	-$35M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	15%	11%	24%	8%	4%	6%	5%	4%
ROA	-	11%	24%	11%	8%	9%	10%	11%
ROE	-	20%	39%	10%	6%	9%	8%	9%

Bad Net Margins (4.44%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	1.64	0.35	2.1	0	0.37	3.03	-0.6
Debt over Equity	0	0.21	0.09	0.06	0	0.06	0.03	0.03
Growth Stability	-	-	-	55%	38%	66%	100%	38%

Good Debt/FCF ratio (-0.6)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0.03)

The company is not overleveraged and has a good balance between equity and debt.

Bad Graham’s Stability (38%)

The company has a bad stability in its earnings, which is a sign of a bad competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	24%	64%	-11%	19%	32%	23%	17%
Earnings YoY growth	-	-10%	270%	-71%	-32%	65%	10%	-18%
Equity YoY growth	-	25%	87%	16%	2%	17%	17%	13%
FCF YoY growth	-	-65%	287%	-88%	76%	294%	-93%	-21%